SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (`Catalent`) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the `Operating Subsidiary`), intends to offer, subject to market and other conditions, EUR450.0 million in aggregate principal amount ($492.8 million U.S. dollar equivalent) of senior unsecured notes due 2028 (the `Notes`) in a private offering (the `Private Offering`) that is exempt from the registration requirements of the Securities Act of 1933, as amended...
|
